Aylin Yucel
University of Houston
13 Papers
7 Citations
Aylin Yucel is an academic researcher from University of Houston. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 10 publications. Previous affiliations of Aylin Yucel include Amgen & University of South Carolina.
Chat about Author
Papers
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
Sophie Park,Peter L. Greenberg,Aylin Yucel,Caroline Farmer,Frank O'Neill,Cisio De Oliveira Brandao,Pierre Fenaux +6 more
TL;DR: ESA therapy should be the foremost first‐line treatment of anaemia in most patients with lower‐risk MDS who lack the 5q deletion, and studies indicated a clinical benefit of ESAs, with benefits observed across key clinical outcomes.
49
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Ali T. Taher,Maria Domenica Cappellini,Antonis Kattamis,Ersi Voskaridou,Silverio Perrotta,Antonio Piga,Aldo Filosa,John B. Porter,Thomas J. Coates,Gian Luca Forni,Alexis A. Thompson,Immacolata Tartaglione,Khaled M. Musallam,Jay Backstrom,Oriana Esposito,Ana Carolina Giuseppi,Wen Ling Kuo,Dimana O. Miteva,Jennifer Lord-Bessen,Aylin Yucel,Tatiana Zinger,Jeevan K. Shetty,Vip Viprakasit +22 more
TL;DR: Luspatercept is a potential treatment for adult patients with non-transfusion-dependent β-thalassaemia, for whom effective approved treatment options are scarce as mentioned in this paper .
35
Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method
TL;DR: The safety of PPI use with respect to DDIs is critically evaluated with a meta-review of systematic reviews published between 1978 and 2015, assessing the evidence by their reliability, repeatability, transparency, and objectivity.
25
Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders.
Aylin Yucel,Swarnava Sanyal,Ekere James Essien,Osaro Mgbere,Rajender R. Aparasu,Vinod S. Bhatara,Joy Alonzo,Hua Chen +7 more
TL;DR: The specialty of provider who initiated MDD care had limited impact on treatment quality and was not associated with the racial/ethnic variations in treatment completion and mental health-related hospitalizations.
11
•Journal Article
The long-term social value of granulocyte colony-stimulating factors.
Alison Sexton Ward,Mina Kabiri,Aylin Yucel,Alison R. Silverstein,Emma van Eijndhoven,Charles Bowers,Mark Bensink,Dana Goldman +7 more
TL;DR: Targeting G- CSF prophylaxis to align with guidelines would more than double SV, highlighting the substantial value of appropriate FN risk assessment and targeted G-CSF proPHylaxis.
6